Evicenter
P&T meetings

Juvmo (tavapadon)

Parkinson's disease

Also known as CVL-751
Manufacturer
AbbVie
Regulatory submission
NDA submitted September 2025
Last updated
217 sources

Product information and disease descriptionProduct descriptionProduct information

Average sales price and wholesale acquisition cost

9 evidence topics · 10 sources

Reported list price of tavapadon, attributed to a William Blair analyst and to ICER public meeting slides; no AbbVie price statement published

“Matt Phipps notes that Juvmo carries a list price of $4,900 per 30-day supply, or $58,800 annually.” (opens the source at this quote in a new tab)

DrugQuoted estimateQuoted annual cost used in model
Tavapadon“Reported WAC”“$58,800”
Launch pricing not disclosed at approval

“AbbVie did not respond to a Reuters request for comment on the drug’s launch and pricing.” (opens the source at this quote in a new tab)

Placeholder annual price and comparator annual drug costs used in the ICER evidence report

“Because tavapadon had not yet received regulatory approval, a placeholder price of $15,000 per year (as reported by IPD Analytics) was used as the intervention acquisition cost in both models. In Model 1, levodopa was costed at the median generic wholesale acquisition cost (WAC) from RED BOOK ($289 per year), consistent with ICER Reference Case guidance for generic agents. In Model 2, the dopamine agonist comparator used a market-basket approach: market-share weights were derived from a 2024 Merative MarketScan Medicare Supplemental analysis restricted to the three most-dispensed agents and normalized to 100% (ropinirole 51.9%, pramipexole 41.6%, rotigotine 6.4%), and annual WAC for each agent was sourced from RED BOOK (with the SSR Health net price applied for rotigotine), yielding a weighted-average annual dopamine agonist cost of $3,588.” (opens the source at this quote in a new tab)

Branded and generic Parkinson's disease comparators: United States National Average Drug Acquisition Cost, week of 23 September 2026
Product and strengthQuoted record descriptionQuoted acquisition cost per unitQuoted pricing unit
Opicapone 50 mg capsule“ONGENTYS 50 MG CAPSULE”“24.76028”“EA”
Safinamide 100 mg tablet“XADAGO 100 MG TABLET”“36.32581”“EA”
Carbidopa-levodopa extended-release 36.25 mg-145 mg capsule“RYTARY ER 36.25 MG-145 MG CAP”“3.97630”“EA”
Pramipexole 1 mg tablet (generic)“PRAMIPEXOLE 1 MG TABLET”“0.06192”“EA”
Ropinirole 3 mg tablet (generic)“ROPINIROLE HCL 3 MG TABLET”“0.07680”“EA”
Carbidopa-levodopa 25-100 mg tablet (generic)“CARBIDOPA-LEVODOPA 25-100 TAB”“0.07589”“EA”
Rotigotine, monoamine oxidase B inhibitor, catechol-O-methyltransferase inhibitor, and amantadine comparators: United States National Average Drug Acquisition Cost, week of 23 September 2026
Product and strengthQuoted record descriptionQuoted acquisition cost per unitQuoted pricing unit
Rotigotine 2 mg/24 hours transdermal patch (Neupro)“NEUPRO 2 MG”/ “24 HR PATCH”“28.26022”“EA”
Rasagiline 1 mg tablet (generic)“RASAGILINE MESYLATE 1 MG TAB”“0.92551”“EA”
Selegiline 5 mg capsule (generic)“SELEGILINE HCL 5 MG CAPSULE”“0.75631”“EA”
Entacapone 200 mg tablet (generic)“ENTACAPONE 200 MG TABLET”“0.32457”“EA”
Carbidopa-levodopa-entacapone 25-100-200 mg tablet (generic)“CARBIDOPA-LEVODOPA-ENTACAPONE 25-100-200 MG TAB”“0.69542”“EA”
Amantadine 100 mg capsule (generic)“AMANTADINE 100 MG CAPSULE”“0.14251”“EA”
Gocovri and Nourianz: wholesale acquisition cost filings with the California Department of Health Care Access and Information
Product and packageQuoted manufacturerQuoted drug product descriptionQuoted WAC effective dateQuoted WAC increase amount (USD)Quoted WAC after increase (USD)
Gocovri (amantadine extended-release) 137 mg, 60 capsules“Adamas Pharmaceuticals, Inc.”“Gocovri Oral Capsule Extended Release 24 Hour 137 MG Package Size 60 Package Quantity 1”“01/01/2023”“149.67”“3142.96”
Nourianz (istradefylline) 20 mg, 90 tablets“Kyowa Kirin, Inc.”“Nourianz Oral Tablet 20 MG, 90 Each, Bottle”“01/05/2024”“270.39”“5678.15”
Nourianz (istradefylline) 40 mg, 90 tablets“Kyowa Kirin, Inc.”“Nourianz Oral Tablet 40 MG, 90 Each, Bottle”“01/05/2024”“270.39”“5678.15”
Branded Parkinson's disease adjunctive therapies: Medicare Part D spending, 2024
Brand (generic)Quoted total spending, 2024 (USD)Quoted beneficiaries, 2024Quoted average spending per dosage unit, 2024 (USD)Quoted average spending per beneficiary, 2024 (USD)
Ongentys (opicapone)“15354274.26”“3276”“21.749437532”“4686.8969048”
Xadago (safinamide)“7677985.91”“759”“37.323213575”“10115.923465”
Nourianz (istradefylline)“50721486.03”“3610”“62.728700759”“14050.273139”
Neupro (rotigotine)“90068151.36”“14920”“27.60090549”“6036.7393673”
Gocovri (amantadine extended-release)“99842781.69”“4906”“55.422069989”“20351.15811”
Inbrija (inhaled levodopa)“27688440.22”“2431”“20.495381225”“11389.732711”
Rytary (carbidopa-levodopa extended-release)“271784313.29”“34890”“4.2578095671”“7789.7481596”
Monoamine oxidase B inhibitors, catechol-O-methyltransferase inhibitors, and amantadine products: Medicare Part D beneficiaries, claims, and spending per dosage unit, 2024
Brand name in the record (generic)Quoted beneficiaries, 2024Quoted claims, 2024Quoted average spending per dosage unit, 2024 (USD)
Rasagiline Mesylate (rasagiline, generic)“31737”“146909”“3.2972061315”
Selegiline HCl (selegiline, generic)“11299”“50495”“0.9994398084”
Xadago (safinamide)“759”“4385”“37.323213575”
Entacapone (entacapone, generic)“26289”“128596”“0.9670266984”
Carbidopa-Levodopa-Entacapone (carbidopa, levodopa, and entacapone, generic)“9136”“50738”“1.3434262576”
Ongentys (opicapone)“3276”“16686”“21.749437532”
Amantadine (amantadine, generic)“104318”“526882”“0.5229425868”
Gocovri (amantadine extended-release)“4906”“30705”“55.422069989”
Out-of-pocket costs of Parkinson's disease medications after generic entry, United States commercial claims

“We identified 186,144 patients with epilepsy, 54,676 with MS, 45,909 with PD, 169,127 with PN, and 60,861 with dementia/Alzheimer.” (opens the source at this quote in a new tab)

“Decreases ranging from 48% to 80% in annual OOP costs of duloxetine, pregabalin, rasagiline, rivastigmine, and memantine were observed in the years after generic introduction.” (opens the source at this quote in a new tab)